“Meet-URO Score Validation in Real-World Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib: A Subanalysis of the Prospective ProPAXI Study”. 2025. Journal of Kidney Cancer 12 (4): 7-18. https://doi.org/10.15586/jkcvhl.v12i4.403.